AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval

Long Wait For First Tremelimumab Approval Could Soon Be Over

 
• By Andrew McConaghie
  
Astrazeneca
AstraZeneca could gain its first approval for the immunotherapy combination by the end of 2022 - but rivals Roche have a head start in liver cancer. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip